Campylobacter jejuni and cytomegalovirus (CMV) infections in patients with the Guillain-Barre syndrome
Guillain-Barre syndrome (GBS) is a rare disease triggered by postinfectious mechanisms. The disease concerns all ages, and is widely distributed around the world. The principal risks are respiratory failure, especially during the initial phase of the disease, and persisting deficit at long term. Amo...
Gespeichert in:
| Veröffentlicht in: | Archives de pédiatrie : organe officiel de la Société française de pédiatrie 2006-12, Vol.13 (12), p.1561-1565 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1565 |
|---|---|
| container_issue | 12 |
| container_start_page | 1561 |
| container_title | Archives de pédiatrie : organe officiel de la Société française de pédiatrie |
| container_volume | 13 |
| creator | Orlikowski, D Quijano-Roy, S Sivadon-Tardy, V Raphael, J-C Gaillard, J-L |
| description | Guillain-Barre syndrome (GBS) is a rare disease triggered by postinfectious mechanisms. The disease concerns all ages, and is widely distributed around the world. The principal risks are respiratory failure, especially during the initial phase of the disease, and persisting deficit at long term. Among the infectious known agents, Campylobacter jejuni and CMV represent more than 40% of GBS causes. The clinical presentation, and the long-term prognosis of GBS related to these two etiologies are different. The physiopathological mechanisms of the nervous attack are probably also different. There is no proof, at this time, that anti-infectious treatment can improve the prognosis. The treatment is based on the early use of immunomodulatory treatments like intravenous immunoglobulins or plasma exchanges. |
| doi_str_mv | 10.1016/j.arcped.2006.09.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68258027</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68258027</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-41b9aacc104625b372281745c48caf4e7a64065c2fb2781814fd95ceef2d9f713</originalsourceid><addsrcrecordid>eNo1kEtLxDAYRbNQnPHxD0SyEl20fklfyVKLjsKIGxV3JU0TJ6VNa5Iq_fcWHFf3Lg6Hy0XonEBMgOQ3bSycHFUTU4A8Bh4D0AO0Bk55lPPkY4WOvW8BgAFLjtCKFJAAIXyNdCn6ce6GWsigHG5VO1mDhW2wnMPQq0_RDd_GTR5flc_v19hYrWQwg_VLxaMIRtng8Y8JOxx2Cm8m03XC2OhOOKewn23jFs0pOtSi8-psnyfo7eH-tXyMti-bp_J2G40k4SFKSc2FkJJAmtOsTgpKGSnSTKZMCp2qQuQp5JmkuqYFI4ykuuGZVErThuuCJCfo8s87uuFrUj5UvfFSLZOsGiZf5YxmDGixgBd7cKp71VSjM71wc_X_TPILVXFmtA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68258027</pqid></control><display><type>article</type><title>Campylobacter jejuni and cytomegalovirus (CMV) infections in patients with the Guillain-Barre syndrome</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Orlikowski, D ; Quijano-Roy, S ; Sivadon-Tardy, V ; Raphael, J-C ; Gaillard, J-L</creator><creatorcontrib>Orlikowski, D ; Quijano-Roy, S ; Sivadon-Tardy, V ; Raphael, J-C ; Gaillard, J-L</creatorcontrib><description>Guillain-Barre syndrome (GBS) is a rare disease triggered by postinfectious mechanisms. The disease concerns all ages, and is widely distributed around the world. The principal risks are respiratory failure, especially during the initial phase of the disease, and persisting deficit at long term. Among the infectious known agents, Campylobacter jejuni and CMV represent more than 40% of GBS causes. The clinical presentation, and the long-term prognosis of GBS related to these two etiologies are different. The physiopathological mechanisms of the nervous attack are probably also different. There is no proof, at this time, that anti-infectious treatment can improve the prognosis. The treatment is based on the early use of immunomodulatory treatments like intravenous immunoglobulins or plasma exchanges.</description><identifier>ISSN: 0929-693X</identifier><identifier>DOI: 10.1016/j.arcped.2006.09.002</identifier><identifier>PMID: 17030119</identifier><language>fre</language><publisher>France</publisher><subject>Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Campylobacter Infections - complications ; Campylobacter Infections - diagnosis ; Campylobacter jejuni ; Child ; Cytomegalovirus Infections - complications ; Cytomegalovirus Infections - diagnosis ; Female ; Guillain-Barre Syndrome - diagnosis ; Guillain-Barre Syndrome - drug therapy ; Guillain-Barre Syndrome - epidemiology ; Guillain-Barre Syndrome - etiology ; Guillain-Barre Syndrome - immunology ; Guillain-Barre Syndrome - therapy ; Humans ; Immunoglobulins, Intravenous - therapeutic use ; Immunologic Factors - therapeutic use ; Incidence ; Male ; Middle Aged ; Plasma Exchange ; Prognosis ; Respiration, Artificial ; Risk Factors</subject><ispartof>Archives de pédiatrie : organe officiel de la Société française de pédiatrie, 2006-12, Vol.13 (12), p.1561-1565</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17030119$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orlikowski, D</creatorcontrib><creatorcontrib>Quijano-Roy, S</creatorcontrib><creatorcontrib>Sivadon-Tardy, V</creatorcontrib><creatorcontrib>Raphael, J-C</creatorcontrib><creatorcontrib>Gaillard, J-L</creatorcontrib><title>Campylobacter jejuni and cytomegalovirus (CMV) infections in patients with the Guillain-Barre syndrome</title><title>Archives de pédiatrie : organe officiel de la Société française de pédiatrie</title><addtitle>Arch Pediatr</addtitle><description>Guillain-Barre syndrome (GBS) is a rare disease triggered by postinfectious mechanisms. The disease concerns all ages, and is widely distributed around the world. The principal risks are respiratory failure, especially during the initial phase of the disease, and persisting deficit at long term. Among the infectious known agents, Campylobacter jejuni and CMV represent more than 40% of GBS causes. The clinical presentation, and the long-term prognosis of GBS related to these two etiologies are different. The physiopathological mechanisms of the nervous attack are probably also different. There is no proof, at this time, that anti-infectious treatment can improve the prognosis. The treatment is based on the early use of immunomodulatory treatments like intravenous immunoglobulins or plasma exchanges.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Campylobacter Infections - complications</subject><subject>Campylobacter Infections - diagnosis</subject><subject>Campylobacter jejuni</subject><subject>Child</subject><subject>Cytomegalovirus Infections - complications</subject><subject>Cytomegalovirus Infections - diagnosis</subject><subject>Female</subject><subject>Guillain-Barre Syndrome - diagnosis</subject><subject>Guillain-Barre Syndrome - drug therapy</subject><subject>Guillain-Barre Syndrome - epidemiology</subject><subject>Guillain-Barre Syndrome - etiology</subject><subject>Guillain-Barre Syndrome - immunology</subject><subject>Guillain-Barre Syndrome - therapy</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Plasma Exchange</subject><subject>Prognosis</subject><subject>Respiration, Artificial</subject><subject>Risk Factors</subject><issn>0929-693X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtLxDAYRbNQnPHxD0SyEl20fklfyVKLjsKIGxV3JU0TJ6VNa5Iq_fcWHFf3Lg6Hy0XonEBMgOQ3bSycHFUTU4A8Bh4D0AO0Bk55lPPkY4WOvW8BgAFLjtCKFJAAIXyNdCn6ce6GWsigHG5VO1mDhW2wnMPQq0_RDd_GTR5flc_v19hYrWQwg_VLxaMIRtng8Y8JOxx2Cm8m03XC2OhOOKewn23jFs0pOtSi8-psnyfo7eH-tXyMti-bp_J2G40k4SFKSc2FkJJAmtOsTgpKGSnSTKZMCp2qQuQp5JmkuqYFI4ykuuGZVErThuuCJCfo8s87uuFrUj5UvfFSLZOsGiZf5YxmDGixgBd7cKp71VSjM71wc_X_TPILVXFmtA</recordid><startdate>200612</startdate><enddate>200612</enddate><creator>Orlikowski, D</creator><creator>Quijano-Roy, S</creator><creator>Sivadon-Tardy, V</creator><creator>Raphael, J-C</creator><creator>Gaillard, J-L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200612</creationdate><title>Campylobacter jejuni and cytomegalovirus (CMV) infections in patients with the Guillain-Barre syndrome</title><author>Orlikowski, D ; Quijano-Roy, S ; Sivadon-Tardy, V ; Raphael, J-C ; Gaillard, J-L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-41b9aacc104625b372281745c48caf4e7a64065c2fb2781814fd95ceef2d9f713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Campylobacter Infections - complications</topic><topic>Campylobacter Infections - diagnosis</topic><topic>Campylobacter jejuni</topic><topic>Child</topic><topic>Cytomegalovirus Infections - complications</topic><topic>Cytomegalovirus Infections - diagnosis</topic><topic>Female</topic><topic>Guillain-Barre Syndrome - diagnosis</topic><topic>Guillain-Barre Syndrome - drug therapy</topic><topic>Guillain-Barre Syndrome - epidemiology</topic><topic>Guillain-Barre Syndrome - etiology</topic><topic>Guillain-Barre Syndrome - immunology</topic><topic>Guillain-Barre Syndrome - therapy</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Plasma Exchange</topic><topic>Prognosis</topic><topic>Respiration, Artificial</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orlikowski, D</creatorcontrib><creatorcontrib>Quijano-Roy, S</creatorcontrib><creatorcontrib>Sivadon-Tardy, V</creatorcontrib><creatorcontrib>Raphael, J-C</creatorcontrib><creatorcontrib>Gaillard, J-L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Archives de pédiatrie : organe officiel de la Société française de pédiatrie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orlikowski, D</au><au>Quijano-Roy, S</au><au>Sivadon-Tardy, V</au><au>Raphael, J-C</au><au>Gaillard, J-L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Campylobacter jejuni and cytomegalovirus (CMV) infections in patients with the Guillain-Barre syndrome</atitle><jtitle>Archives de pédiatrie : organe officiel de la Société française de pédiatrie</jtitle><addtitle>Arch Pediatr</addtitle><date>2006-12</date><risdate>2006</risdate><volume>13</volume><issue>12</issue><spage>1561</spage><epage>1565</epage><pages>1561-1565</pages><issn>0929-693X</issn><abstract>Guillain-Barre syndrome (GBS) is a rare disease triggered by postinfectious mechanisms. The disease concerns all ages, and is widely distributed around the world. The principal risks are respiratory failure, especially during the initial phase of the disease, and persisting deficit at long term. Among the infectious known agents, Campylobacter jejuni and CMV represent more than 40% of GBS causes. The clinical presentation, and the long-term prognosis of GBS related to these two etiologies are different. The physiopathological mechanisms of the nervous attack are probably also different. There is no proof, at this time, that anti-infectious treatment can improve the prognosis. The treatment is based on the early use of immunomodulatory treatments like intravenous immunoglobulins or plasma exchanges.</abstract><cop>France</cop><pmid>17030119</pmid><doi>10.1016/j.arcped.2006.09.002</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0929-693X |
| ispartof | Archives de pédiatrie : organe officiel de la Société française de pédiatrie, 2006-12, Vol.13 (12), p.1561-1565 |
| issn | 0929-693X |
| language | fre |
| recordid | cdi_proquest_miscellaneous_68258027 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adolescent Adult Age Factors Aged Aged, 80 and over Campylobacter Infections - complications Campylobacter Infections - diagnosis Campylobacter jejuni Child Cytomegalovirus Infections - complications Cytomegalovirus Infections - diagnosis Female Guillain-Barre Syndrome - diagnosis Guillain-Barre Syndrome - drug therapy Guillain-Barre Syndrome - epidemiology Guillain-Barre Syndrome - etiology Guillain-Barre Syndrome - immunology Guillain-Barre Syndrome - therapy Humans Immunoglobulins, Intravenous - therapeutic use Immunologic Factors - therapeutic use Incidence Male Middle Aged Plasma Exchange Prognosis Respiration, Artificial Risk Factors |
| title | Campylobacter jejuni and cytomegalovirus (CMV) infections in patients with the Guillain-Barre syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T20%3A31%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Campylobacter%20jejuni%20and%20cytomegalovirus%20(CMV)%20infections%20in%20patients%20with%20the%20Guillain-Barre%20syndrome&rft.jtitle=Archives%20de%20p%C3%A9diatrie%20:%20organe%20officiel%20de%20la%20Soci%C3%A9t%C3%A9%20fran%C3%A7aise%20de%20p%C3%A9diatrie&rft.au=Orlikowski,%20D&rft.date=2006-12&rft.volume=13&rft.issue=12&rft.spage=1561&rft.epage=1565&rft.pages=1561-1565&rft.issn=0929-693X&rft_id=info:doi/10.1016/j.arcped.2006.09.002&rft_dat=%3Cproquest_pubme%3E68258027%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68258027&rft_id=info:pmid/17030119&rfr_iscdi=true |